Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join – Contact The Gross Law Firm

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering and subsequent merger with AbbVie Inc. [1] Group 1: Allegations and Details - The lawsuit claims that Cerevel's October 16, 2023 secondary stock offering documents omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which artificially deflated Cerevel's stock price until the merger announcement [4] - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at the depressed price while possessing nonpublic information about AbbVie's interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [4] - Cerevel's January 18, 2024 Proxy statement is accused of misleading investors regarding the nature and timing of AbbVie's interest in the company [4] Group 2: Class Action Participation - Shareholders who purchased shares of Cerevel during the class period from October 11, 2023, to August 1, 2024, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for June 3, 2025 [3][5] - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's status [5] Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [6]